Skip to main content

Tanguler Tolga's Form 4 filing

Alnylam Pharmaceuticals, Inc. (ALNY) · filed Aug 19, 2025

Accession no.
0001735276-25-000091
Filed
Aug 19, 2025
Trade date
Aug 15-18, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 9 non-derivative transactions. Open-market sales total $632.8K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Tanguler TolgaCIK 0001849458Officer (EVP, Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 15, 2025Common StockAGrant or awardAcquired+2,851$0.00$030,862Direct
Aug 18, 2025Common StockSSaleDisposed−39$447.98−$17,471.2230,823Direct
Aug 18, 2025Common StockSSaleDisposed−90$449.92−$40,492.830,733Direct
Aug 18, 2025Common StockSSaleDisposed−39$450.92−$17,585.8830,694Direct
Aug 18, 2025Common StockSSaleDisposed−103$451.99−$46,554.9730,591Direct
Aug 18, 2025Common StockSSaleDisposed−329$452.96−$149,023.8430,262Direct
Aug 18, 2025Common StockSSaleDisposed−543$454.04−$246,543.7229,719Direct
Aug 18, 2025Common StockSSaleDisposed−241$454.84−$109,616.4429,478Direct
Aug 18, 2025Common StockSSaleDisposed−12$455.82−$5,469.8429,466Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)